Biokin's BL-M07D1 Initiates Phase III Trial for HER2-Positive Biliary Tract Cancer
May 26, 2026 15:35
CST Updated
18:01
Biokin
Pharmaceutical R&D Developer
Daiichi - Sankyo
Pharmaceutical Development, Production, Sales, and Consulting Service Provider
AstraZeneca
Pharmaceutical Technology Research and Development Provider